A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse

References

• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-Cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–551.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579–2581.
   PubMed Web of Science ®Google Scholar
• Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622.
   PubMed Web of Science ®Google Scholar
• Armand P, Welch S, Kim HT, et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013;160(5):608–617.
   PubMed Web of Science ®Google Scholar
• Yhim H-Y, Eshet Y, Metser U, et al. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant deauville score. Blood Adv. 2020;4(22):5762–5771.
   PubMed Web of Science ®Google Scholar
• Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era? Blood. 2021;137(10):1416–1423.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Locke F. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma. 63rd ASH Annual Meeting and Exposition; ASH. 2021, December 11–14, Atlanta, GA, United States.
   Google Scholar
• Bishop M. Tisagenlecleucel vs. standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study. 63rd ASH Annual Meeting and Exposition; ASH. 2021, December 11-14, Atlanta, GA, United States.
   Google Scholar
• Kamdar M. Lisocabtagene Maraleucel (liso-cel), a CD19-directed Chimeric Antigen Receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. 63rd ASH Annual Meeting and Exposition; ASH. 2021, December 11-14, Atlanta, GA, United States.
   Google Scholar
• Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–1154.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Zwezerijnen BGJC, de Vet HCW, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-Cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62(3):332–337.
   PubMed Web of Science ®Google Scholar
• Capobianco N, Meignan M, Cottereau A-S, et al. Bruce spottiswoode; sven zuehlsdorff; olivier casasnovas; catherine thieblemont; irene buvat. Fully automated deep learning FDG uptake classification enables total metabolic tumor volume (MTV) estimation in diffuse large B-cell lymphoma with similar predictive value as expert MTV measurements. J Nucl Med. 2021;62(1):30–36.
   PubMedGoogle Scholar
• Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–1219.
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Kuker RA, Barreto-Coelho P, et al. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;20:1–11. doi:https://doi.org/10.1080/10428194.2021.1966786.
   Google Scholar
• Cherng HJ, Chuang HH, Steiner R, et al. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;26:1–10. doi: https://doi.org/10.1080/10428194.2021.1971223.
   Google Scholar
• Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607–5615.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu Y, Yang S, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with Non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–1098.
   PubMed Web of Science ®Google Scholar
• Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268–3276.
   PubMed Web of Science ®Google Scholar